FDA panel gives nod to Merck's Vytorin - Cardiovascular Business PDF Print
Cardiovascular Business
2 to recommend Merck's Vytorin (combination ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease. However, when it came to whether or not the approval should include patients with end-stage renal disease receiving

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.